Abbott Laboratories (NYSE:ABT) Issues Q3 2025 Earnings Guidance

Abbott Laboratories (NYSE:ABT - Get Free Report) updated its third quarter 2025 earnings guidance on Thursday. The company provided earnings per share guidance of 1.280-1.320 for the period, compared to the consensus earnings per share estimate of 1.338. The company issued revenue guidance of -. Abbott Laboratories also updated its FY 2025 guidance to 5.100-5.200 EPS.

Abbott Laboratories Trading Up 2.7%

ABT stock traded up $3.30 during midday trading on Friday, reaching $123.81. The stock had a trading volume of 19,570,335 shares, compared to its average volume of 6,224,928. The business has a fifty day simple moving average of $132.98 and a two-hundred day simple moving average of $129.56. The firm has a market cap of $215.41 billion, a price-to-earnings ratio of 15.52, a PEG ratio of 2.35 and a beta of 0.73. The company has a quick ratio of 1.27, a current ratio of 1.78 and a debt-to-equity ratio of 0.26. Abbott Laboratories has a twelve month low of $99.92 and a twelve month high of $141.23.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $1.26. The business had revenue of $11.14 billion for the quarter, compared to the consensus estimate of $11.01 billion. Abbott Laboratories had a return on equity of 18.83% and a net margin of 32.43%. Abbott Laboratories's quarterly revenue was up 7.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.14 earnings per share. As a group, research analysts expect that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 15th. Investors of record on Tuesday, July 15th will be given a $0.59 dividend. This represents a $2.36 annualized dividend and a dividend yield of 1.91%. The ex-dividend date is Tuesday, July 15th. Abbott Laboratories's dividend payout ratio (DPR) is 29.57%.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ABT. Stifel Nicolaus boosted their price objective on shares of Abbott Laboratories from $135.00 to $145.00 and gave the company a "buy" rating in a research report on Thursday, April 17th. Piper Sandler reissued an "overweight" rating and issued a $145.00 target price (up from $133.00) on shares of Abbott Laboratories in a research report on Thursday, April 17th. Jefferies Financial Group upgraded Abbott Laboratories from a "hold" rating to a "buy" rating and raised their target price for the company from $143.00 to $145.00 in a research report on Friday. Leerink Partnrs upgraded shares of Abbott Laboratories to a "hold" rating in a report on Monday, June 16th. Finally, Leerink Partners started coverage on shares of Abbott Laboratories in a research report on Monday, June 16th. They set a "market perform" rating and a $143.00 price target for the company. Five analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $144.47.

Insider Buying and Selling at Abbott Laboratories

In related news, Director Sally E. Blount sold 2,600 shares of the firm's stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $129.66, for a total value of $337,116.00. Following the completion of the transaction, the director directly owned 34,058 shares of the company's stock, valued at $4,415,960.28. This trade represents a 7.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.46% of the company's stock.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Abbott Laboratories stock. Brighton Jones LLC lifted its holdings in Abbott Laboratories (NYSE:ABT - Free Report) by 10.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 51,719 shares of the healthcare product maker's stock after purchasing an additional 4,755 shares during the quarter. Brighton Jones LLC's holdings in Abbott Laboratories were worth $5,850,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 75.18% of the company's stock.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.